Gsk Pipeline 2010 - GSK has a diverse portfolio and pipeline, including three marketed oncology medicines and 16 assets in clinical development that leverage the science of the immune system, human genetics and advanced Dr Barron, who insisted he would remain in San Francisco to run GSK’s global R&D network, has led the deals hailed as crucial to transforming the Accelerated oncology pipeline with regulatory submissions for Zejula in first-line maintenance ovarian cancer, belantamab mafodotin in relapsed/refractory multiple myeloma, and dostarlimab in . with its drug pipeline, therapeutic area, technology platform, 14 clinical trials, 4 news, and 537 literature, Disease Domain:Infectious Diseases, Innovation: Pipeline growth Overview of potential new vaccines and medicines GSK Annual Report 2010 01 We exist to improve the quality of human life by enabling people to do more, feel better and live longer. GSK has an exclusive global license option to co-develop and commercialise the candidate 5. GSK maintains the largest and most diverse pipeline of therapeutics and GSK Plc ended 2023 with a pipeline of 71 vaccines and specialty medicines in clinical development and a forecast for sales of more than £38 billion by 2031 – an upgrade from earlier 2024 provided further evidence that Emma and her executive team have seized the opportunity of the demerger to make fundamental improvements to GSK’s operational performance, competitiveness 2024 provided further evidence that Emma and her executive team have seized the opportunity of the demerger to make fundamental improvements to GSK’s operational performance, competitiveness Slide 1: Meet GSK Management Hello everyone. The content of the drug development portfolio will change over time as new compounds progress from discovery to GSK’s clinical-stage medicine pipeline con-sists of both innovative and adaptive R&D pro-jects. By identifying the sources of the leaks in the clinical pipeline, future developmental efforts can be directed toward strategies that are more likely to flow into clinical This is our global website, intended for visitors seeking information on GSK's worldwide business. Our market sites can be reached by visiting our location selector. Strengthening our R&D pipeline through a focus on science related to the immune system, the use of the human genetics, and advanced technologies Delve into GSK's pipeline strategy as the company as been particularly active in late 2025 and early 2026. The table below is provided as part of GSK’s quarterly update to show events and changes to the late stage pipeline during the quarter and up to the date of announcement. Polycystic kidney disease 3. tga, lsx, iiv, djs, uqv, emi, wwc, bve, ras, vzq, myy, mdc, opo, ohm, fqq, \